Omeros Corporation (OMER)
NASDAQ:OMER
Want to see OMER full AI Analyst Report?
OMER Stock Chart & Stats
$13.44
-$0.23(-2.31%)
At close: 4:00 PM EST
$13.44
-$0.23(-2.31%)
Day’s Range― - ―
52-Week Range$2.95 - $17.65
Previous CloseN/A
Volume193.12K
Average Volume (3M)1.30M
Market Cap
$829.42M
Enterprise Value$1.14B
Total Cash (Recent Filing)$135.32M
Total Debt (Recent Filing)$310.63M
Price to Earnings (P/E)3.4
Beta1.07
Next Earnings
Aug 12, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.30
Shares Outstanding72,375,360
10 Day Avg. Volume1,736,146
30 Day Avg. Volume1,295,970
Financial Highlights & Ratios
PEG Ratio3.32
Price to Book (P/B)-9.00
Price to Sales (P/S)0.00
P/FCF Ratio-9.39
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue115.05
Enterprise Value/Gross Profit-928.34
Enterprise Value/Ebitda-10.91
Forecast
1Y Price Target
$40.00Price Target Upside197.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$71.15M
Bulls Say, Bears Say
Bulls Say
Cash Flow OutlookManagement expects the Yartemlea business to become self-sustaining and generate positive cash flow within the company’s forecast horizon, enabling reinvestment into the pipeline and potential partnerships.
Pipeline AdvancementOncotoX-AML preclinical results showed selective reduction of malignant myeloid cells while preserving stem cells and delivered stronger tumor control in animal studies, supporting advancement toward human trials.
Product Launch MomentumRapid engagement with transplant centers, early formulary wins, and minimal reimbursement friction are translating into utilization for Yartemlea and support upside to near-term revenue expectations.
Bears Say
Disclosure And VisibilityThe company disclosed limited quantitative details about the Yartemlea launch, creating uncertainty around commercial performance and making revenue forecasting more difficult for analysts.
Earnings QualityA profit beat driven by recognition of an upfront licensing payment for OMS906 may represent a one-time accounting benefit, introducing risk of earnings volatility and potential overstatement of operational results.
Valuation RiskAnalyst Hold cites that the current valuation already reflects significant expected Yartemlea sales, which could limit upside for the stock if launch outcomes only meet expectations.
Omeros News
OMER FAQ
What was Omeros Corporation’s price range in the past 12 months?
Omeros Corporation lowest stock price was $2.95 and its highest was $17.65 in the past 12 months.
What is Omeros Corporation’s market cap?
Omeros Corporation’s market cap is $829.42M.
When is Omeros Corporation’s upcoming earnings report date?
Omeros Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 80 days.
How were Omeros Corporation’s earnings last quarter?
Currently, no data Available
Is Omeros Corporation overvalued?
According to Wall Street analysts Omeros Corporation’s price is currently Undervalued.
Does Omeros Corporation pay dividends?
Omeros Corporation does not currently pay dividends.
What is Omeros Corporation’s EPS estimate?
Omeros Corporation’s EPS estimate is -0.25.
How many shares outstanding does Omeros Corporation have?
Omeros Corporation has 72,375,360 shares outstanding.
What happened to Omeros Corporation’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Omeros Corporation?
Currently, no hedge funds are holding shares in OMER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.00 (197.62% Upside)
$40.00 (197.62% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 13.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
255.90%
12-Months-Change
Fundamentals
Return on Equity
-54.39%
Trailing 12-Months
Asset Growth
21.69%
Trailing 12-Months
Company Description
Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong positive commercial and regulatory momentum driven by the FDA approval and rapid early launch of YARTEMLEA, meaningful non-dilutive capital from the Novo Nordisk transaction, a solid cash position, and multiple pipeline and scientific milestones. Offsetting factors include an adjusted operating loss (excluding noncash items), earnings volatility from mark-to-market adjustments tied to convertible note derivatives, remaining convertible debt, and the early stage of commercial adoption with limited patient-level disclosure. On balance, the highlights around approval, early revenue, cash infusion, reimbursement progress (J-code and potential NTAP), and broad pipeline progress outweigh the near-term financial and volatility headwinds.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$40.00
▲(197.62% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.73% Insiders
7.92% Mutual Funds
7.49% Other Institutional Investors
69.93% Public Companies and Individual Investors